Skip to content

Efficacy and Safety of AS012 in Subjects With Non-segmental Vitiligo

A Phase II, Randomized, Double Blind, Placebo-Controlled, Dose-Ranging Study to Evaluate the Efficacy and Safety of AS012 in Subjects With Non-segmental Vitiligo

Status
Completed
Phases
Phase 2
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT04487860
Enrollment
327
Registered
2020-07-27
Start date
2021-01-13
Completion date
2023-02-27
Last updated
2025-03-10

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Non-segmental Vitiligo

Brief summary

This is a randomized, double blind, placebo-controlled, phase II study. The study will be performed as a multicenter, multinational study.

Interventions

DRUGPlacebo

oral administration

DRUGAS012

oral administration

Sponsors

Ache Laboratorios Farmaceuticos S.A.
Lead SponsorINDUSTRY

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
QUADRUPLE (Subject, Caregiver, Investigator, Outcomes Assessor)

Eligibility

Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No

Inclusion criteria

1. Provide written informed consent. 2. Male or female ≥ 18 years of age at time of screening 3. Stable (without new patches ≥ 1 year) or unstable (with new patches for the last 1 year) vitiligo 4. VASI of ≥ 4 at screening and baseline

Exclusion criteria

1. Segmental vitiligo, focal, or mixed Vitiligo 2. Subjects who have high risk of suicidality at the Screening assessment based on Investigator's judgment 3. History of alcohol or drug abuse in the previous 2 years 4. Subjects who were submitted to melanocyte transfer \-

Design outcomes

Primary

MeasureTime frameDescription
Mean Change From Baseline in Vitiligo Area Scoring Index ScoreWeek 24Vitiligo Area Scoring Index score: numeric score that can range from 0 to 100, with higher VASI scores denoting poorer the disease state

Secondary

MeasureTime frameDescription
Mean Change From Baseline in Vitiligo Extent Score (VES) on Clinical PicturesWeek 24The Vitiligo Extent Score (VES) measures the overall vitiligo involvement in the body based on clinical pictures reflecting the natural distribution of the disease across 19 body areas (e.g., face, trunk, arms, legs, hands, axillae, back, gluteal). For each area, one representative image is selected, assigning one of six degrees of involvement (1%, 5%, 10%, 25%, 50%, 75%). The total and final score is the sum of the measurements from all areas, calculated using a conversion table available in the online calculator (www.vitiligo-calculator.com), and expressed as the extension of body surface area affected (0-100). Higher scores indicate worse clinical involvement. The VES change from baseline to Week 24 was assessed for the ITT population.
Mean Change in Vitiligo Impact Patient ScaleWeek 24Subjects will be asked to complete a questionnaire to assess the burden experienced by individuals affected. For each of the statements in the Vitiligo Impact Patient Scale, 7 responses are suggested: always, very often, often, sometimes, rarely, never and not applicable. The individual answered as spontaneously as possible while thinking about their situation over the last 7 days. Summary scores range from 0 to 100. Higher values indicate a worse clinical condition.
Physician's Global Assessment ScoresWeek 52Description: The investigator will perform an average assessment of all vitiligo lesions. The following scale will be used for the PGA: Score 0= No involvement, Score 1= Limited, Score 2= moderate, Score 3= Extensive or Score 4= Very extensive. Higher values indicate a worse clinical condition. The static Physician's Global Assessment determines vitiligo extend at a single point in time, without taking the baseline disease condition into consideration, in other words, represents the Proportion of subjects achieving a PGA score of no involvement (score 0) or limited extent (score 1) with at least 2-point reduction from Baseline Week 52.
Mean Change From Baseline in Dermatology Life Quality IndexWeek 52The DLQI scores are based on the response from the patient. Each question is scored from 0 (not affected at all) to 3 (very much affected). The DLQI is calculated by summing the score of each question resulting in a maximum of 30 and a minimum of 0. The higher the score, the more quality of life is impaired OR lower scores indicate better quality of life.

Countries

India, United States

Participant flow

Participants by arm

ArmCount
Placebo
Placebo
59
Placebo to AS012 Dose Regimen II at Week 24
Placebo to AS012 dose 2x at Week 24
20
Placebo to AS012 Dose Regimen IV at Week 24
Placebo to AS012 dose 6x at Week 24
20
AS012 Dose Regimen I
AS012 dose x
62
AS012 Dose Regimen II
AS012 dose 2x
71
AS012 Dose Regimen III
AS012 dose 4x
63
AS012 Dose Regimen IV
AS012 dose 6x
72
Total367

Baseline characteristics

CharacteristicPlaceboAS012 Dose Regimen IAS012 Dose Regimen IIAS012 Dose Regimen IIIAS012 Dose Regimen IVTotalPlacebo to AS012 Dose Regimen II at Week 24Placebo to AS012 Dose Regimen IV at Week 24
Age, Continuous
Placebo and AS012 Regimens
44.2 years
STANDARD_DEVIATION 14.65
48.1 years
STANDARD_DEVIATION 14.85
45.2 years
STANDARD_DEVIATION 12.87
46.8 years
STANDARD_DEVIATION 14.52
41.8 years
STANDARD_DEVIATION 15.18
45.1 years
STANDARD_DEVIATION 14.49
Age, Continuous
Placebo to AS012 Regimens
44.5 years
STANDARD_DEVIATION 15.66
45.6 years
STANDARD_DEVIATION 14.81
43.3 years
STANDARD_DEVIATION 16.76
Ethnicity (NIH/OMB)
Placebo and AS012 Regimens
Hispanic or Latino
19 Participants18 Participants17 Participants15 Participants16 Participants85 Participants0 Participants0 Participants
Ethnicity (NIH/OMB)
Placebo and AS012 Regimens
Not Hispanic or Latino
40 Participants44 Participants54 Participants48 Participants56 Participants242 Participants0 Participants0 Participants
Ethnicity (NIH/OMB)
Placebo and AS012 Regimens
Unknown or Not Reported
0 Participants0 Participants0 Participants0 Participants0 Participants0 Participants0 Participants0 Participants
Ethnicity (NIH/OMB)
Placebo to AS012 Regimens
Hispanic or Latino
0 Participants0 Participants0 Participants0 Participants0 Participants14 Participants8 Participants6 Participants
Ethnicity (NIH/OMB)
Placebo to AS012 Regimens
Not Hispanic or Latino
0 Participants0 Participants0 Participants0 Participants0 Participants26 Participants12 Participants14 Participants
Ethnicity (NIH/OMB)
Placebo to AS012 Regimens
Unknown or Not Reported
0 Participants0 Participants0 Participants0 Participants0 Participants0 Participants0 Participants0 Participants
Sex: Female, Male
Placebo and AS012 Regimens
Female
31 Participants32 Participants38 Participants36 Participants34 Participants171 Participants0 Participants0 Participants
Sex: Female, Male
Placebo and AS012 Regimens
Male
28 Participants30 Participants33 Participants27 Participants38 Participants156 Participants0 Participants0 Participants
Sex: Female, Male
Placebo to AS012 Regimens
Female
0 Participants0 Participants0 Participants0 Participants0 Participants19 Participants11 Participants8 Participants
Sex: Female, Male
Placebo to AS012 Regimens
Male
0 Participants0 Participants0 Participants0 Participants0 Participants21 Participants9 Participants12 Participants

Adverse events

Event typeEG000
affected / at risk
EG001
affected / at risk
EG002
affected / at risk
EG003
affected / at risk
EG004
affected / at risk
EG005
affected / at risk
EG006
affected / at risk
EG007
affected / at risk
EG008
affected / at risk
EG009
affected / at risk
EG010
affected / at risk
EG011
affected / at risk
deaths
Total, all-cause mortality
0 / 590 / 620 / 700 / 630 / 720 / 200 / 200 / 440 / 590 / 460 / 540 / 162
other
Total, other adverse events
0 / 590 / 620 / 700 / 630 / 721 / 200 / 200 / 440 / 590 / 460 / 540 / 162
serious
Total, serious adverse events
0 / 590 / 620 / 700 / 630 / 720 / 200 / 200 / 440 / 590 / 460 / 540 / 162

Outcome results

Primary

Mean Change From Baseline in Vitiligo Area Scoring Index Score

Vitiligo Area Scoring Index score: numeric score that can range from 0 to 100, with higher VASI scores denoting poorer the disease state

Time frame: Week 24

ArmMeasureValue (MEAN)Dispersion
PlaceboMean Change From Baseline in Vitiligo Area Scoring Index Score-0.472 score on a scaleStandard Deviation 1.0422
AS012 Dose Regimen IMean Change From Baseline in Vitiligo Area Scoring Index Score-0.271 score on a scaleStandard Deviation 2.5139
AS012 Dose Regimen IIMean Change From Baseline in Vitiligo Area Scoring Index Score-0.706 score on a scaleStandard Deviation 1.7301
AS012 Dose Regimen IIIMean Change From Baseline in Vitiligo Area Scoring Index Score-1.145 score on a scaleStandard Deviation 2.7721
AS012 Dose Regimen IVMean Change From Baseline in Vitiligo Area Scoring Index Score-0.110 score on a scaleStandard Deviation 2.6168
p-value: 0.7905ANCOVA
p-value: 0.7372ANCOVA
p-value: 0.2989ANCOVA
p-value: 0.3328ANCOVA
Secondary

Mean Change From Baseline in Dermatology Life Quality Index

The DLQI scores are based on the response from the patient. Each question is scored from 0 (not affected at all) to 3 (very much affected). The DLQI is calculated by summing the score of each question resulting in a maximum of 30 and a minimum of 0. The higher the score, the more quality of life is impaired OR lower scores indicate better quality of life.

Time frame: Week 52

ArmMeasureValue (MEAN)Dispersion
PlaceboMean Change From Baseline in Dermatology Life Quality Index0.2 score on a scaleStandard Deviation 2.12
AS012 Dose Regimen IMean Change From Baseline in Dermatology Life Quality Index0.0 score on a scaleStandard Deviation 3.33
AS012 Dose Regimen IIMean Change From Baseline in Dermatology Life Quality Index-0.8 score on a scaleStandard Deviation 3.08
AS012 Dose Regimen IIIMean Change From Baseline in Dermatology Life Quality Index-0.6 score on a scaleStandard Deviation 4.76
AS012 Dose Regimen IVMean Change From Baseline in Dermatology Life Quality Index-2.0 score on a scaleStandard Deviation 3.49
AS012 Dose Regimen IVMean Change From Baseline in Dermatology Life Quality Index-0.2 score on a scaleStandard Deviation 2.51
Secondary

Mean Change From Baseline in Vitiligo Extent Score (VES) on Clinical Pictures

The Vitiligo Extent Score (VES) measures the overall vitiligo involvement in the body based on clinical pictures reflecting the natural distribution of the disease across 19 body areas (e.g., face, trunk, arms, legs, hands, axillae, back, gluteal). For each area, one representative image is selected, assigning one of six degrees of involvement (1%, 5%, 10%, 25%, 50%, 75%). The total and final score is the sum of the measurements from all areas, calculated using a conversion table available in the online calculator (www.vitiligo-calculator.com), and expressed as the extension of body surface area affected (0-100). Higher scores indicate worse clinical involvement. The VES change from baseline to Week 24 was assessed for the ITT population.

Time frame: Week 24

ArmMeasureValue (MEAN)Dispersion
PlaceboMean Change From Baseline in Vitiligo Extent Score (VES) on Clinical Pictures-0.507 score on a scaleStandard Deviation 1.7427
AS012 Dose Regimen IMean Change From Baseline in Vitiligo Extent Score (VES) on Clinical Pictures-0.671 score on a scaleStandard Deviation 2.2065
AS012 Dose Regimen IIMean Change From Baseline in Vitiligo Extent Score (VES) on Clinical Pictures-0.284 score on a scaleStandard Deviation 2.4793
AS012 Dose Regimen IIIMean Change From Baseline in Vitiligo Extent Score (VES) on Clinical Pictures-0.454 score on a scaleStandard Deviation 2.1214
AS012 Dose Regimen IVMean Change From Baseline in Vitiligo Extent Score (VES) on Clinical Pictures-1.218 score on a scaleStandard Deviation 3.3963
p-value: 0.8989ANCOVA
p-value: 0.6768ANCOVA
p-value: 0.8209ANCOVA
p-value: 0.3106ANCOVA
Secondary

Mean Change in Vitiligo Impact Patient Scale

Subjects will be asked to complete a questionnaire to assess the burden experienced by individuals affected. For each of the statements in the Vitiligo Impact Patient Scale, 7 responses are suggested: always, very often, often, sometimes, rarely, never and not applicable. The individual answered as spontaneously as possible while thinking about their situation over the last 7 days. Summary scores range from 0 to 100. Higher values indicate a worse clinical condition.

Time frame: Week 24

ArmMeasureValue (MEAN)Dispersion
PlaceboMean Change in Vitiligo Impact Patient Scale-2.72 score on a scaleStandard Deviation 12.575
AS012 Dose Regimen IMean Change in Vitiligo Impact Patient Scale-3.48 score on a scaleStandard Deviation 13.603
AS012 Dose Regimen IIMean Change in Vitiligo Impact Patient Scale-4.24 score on a scaleStandard Deviation 18.984
AS012 Dose Regimen IIIMean Change in Vitiligo Impact Patient Scale-2.50 score on a scaleStandard Deviation 11.506
AS012 Dose Regimen IVMean Change in Vitiligo Impact Patient Scale-2.06 score on a scaleStandard Deviation 15.082
p-value: 0.8593ANCOVA
p-value: 0.9594ANCOVA
p-value: 0.9041ANCOVA
p-value: 0.7147ANCOVA
Secondary

Physician's Global Assessment Scores

Description: The investigator will perform an average assessment of all vitiligo lesions. The following scale will be used for the PGA: Score 0= No involvement, Score 1= Limited, Score 2= moderate, Score 3= Extensive or Score 4= Very extensive. Higher values indicate a worse clinical condition. The static Physician's Global Assessment determines vitiligo extend at a single point in time, without taking the baseline disease condition into consideration, in other words, represents the Proportion of subjects achieving a PGA score of no involvement (score 0) or limited extent (score 1) with at least 2-point reduction from Baseline Week 52.

Time frame: Week 52

ArmMeasureValue (COUNT_OF_PARTICIPANTS)
PlaceboPhysician's Global Assessment Scores0 Participants
AS012 Dose Regimen IPhysician's Global Assessment Scores0 Participants
AS012 Dose Regimen IIPhysician's Global Assessment Scores0 Participants
AS012 Dose Regimen IIIPhysician's Global Assessment Scores0 Participants
AS012 Dose Regimen IVPhysician's Global Assessment Scores1 Participants
AS012 Dose Regimen IVPhysician's Global Assessment Scores0 Participants

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026